睿知中国医院研究地图
候选清单

正在招募肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06942143,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.

    入选标准第 24 条

    Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;

    排除标准第 1 条

    no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;

    排除标准第 3 条

    Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."

    排除标准第 8 条

  3. ECOG score 0-1;

    入选标准第 8 条

  4. WBC ≥3.0×109/L;

    入选标准第 13 条

    Absolute neutrophil count (ANC) ≥1.5×109/L;

    入选标准第 14 条

    platelet (PLT) ≥75×109/L;

    入选标准第 16 条

    hemoglobin ≥10g/dL (no blood transfusion in the past 7 days);

    入选标准第 17 条

    24-hour creatinine clearance ≥60mL/ min;

    入选标准第 20 条

    Aspartate aminotransferase (AST/SGOT) ≤2.5×ULN;

    入选标准第 21 条

    alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;

    入选标准第 22 条

    Total bilirubin (TBIL) ≤1.5×ULN

    入选标准第 23 条

  5. Measurable lesions according to RECIST1.1 criteria.

    入选标准第 4 条

  6. Pregnant or lactating women;

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06942143,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign informed consent before conducting any trial-related activities;
  2. Age of 18-75 years old, male or female;
  3. Patients with first-line treatment failure;
  4. Measurable lesions according to RECIST1.1 criteria.
  5. During the trial screening period, the following two screening criteria must be met (by the sponsor) :
  6. HLA-A*02 positive;
  7. The positive rate of NYESO-1 immunohistochemical staining was ≥20%.
  8. ECOG score 0-1;
  9. The expected survival time is more than 3 months;
  10. Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion;
  11. Echocardiography showed left ventricular ejection fraction ≥50%;
  12. Laboratory test results should at least meet the following specified indicators:
  13. WBC ≥3.0×109/L;
  14. Absolute neutrophil count (ANC) ≥1.5×109/L;
  15. Absolute lymphocyte count (ALC) ≥1.0×109/L;
  16. platelet (PLT) ≥75×109/L;
  17. hemoglobin ≥10g/dL (no blood transfusion in the past 7 days);
  18. Prothrombin time or INR≤1.5x upper limit of normal unless receiving anticoagulant therapy;
  19. Partial prothrombin time (APTT) ≤1.5x upper limit of normal time, unless receiving anticoagulant therapy;
  20. 24-hour creatinine clearance ≥60mL/ min;
  21. Aspartate aminotransferase (AST/SGOT) ≤2.5×ULN;
  22. alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;
  23. Total bilirubin (TBIL) ≤1.5×ULN
  24. Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.
  25. During the whole period of the trial, I can regularly visit the enrolled research institutions for relevant testing, evaluation and management.

排除标准:Exclusion Criteria:

  1. Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;
  2. Known to produce allergic reactions to any component of the trial treatment;
  3. no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;
  4. Poorly controlled hypertension (systolic blood pressure > 160mmHg and/or diastolic blood pressure > 90mmHg) or clinically significant (e.g., active) cardio-cerebrovascular disease; Cerebrovascular accident (within 6 months before the signing of informed consent), myocardial infarction (within 6 months before the signing of informed consent), unstable angina, congestive heart failure of New York Heart Association class II or higher (Appendix), or severe arrhythmia that could not be controlled with medications or that had the potential to affect study treatment; Electrocardiogram (ECG) was significantly abnormal or the mean QTc interval was ≥450 msec on three consecutive occasions.
  5. Combined with other serious organic diseases and mental disorders;
  6. Have active systemic infection requiring treatment, including active tuberculosis, known HIV positivity, or clinically active hepatitis A, B, or C; (Virus carriers should be excluded)
  7. Patients with autoimmune diseases: those with a history of inflammatory bowel disease or a history of autoimmune diseases (such as systemic lupus erythematosus, vasculitis, and invasive lung disease) judged by the investigators to be not suitable for this study should be excluded; (Patients with vitiligo are not excluded).
  8. Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."
  9. History of organ transplantation, autologous/allogeneic stem cell transplantation and renal replacement therapy;
  10. Known uncontrolled diabetes mellitus, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;
  11. Known alcohol and/or drug abuse;
  12. Pregnant or lactating women;
  13. Trial participants with any coexisting medical conditions or diseases judged by the investigators to be likely to impair the conduct of the trial;
  14. No legal capacity/limited capacity.

引自 ClinicalTrials.gov, NCT06942143, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06942143,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06942143